Home
Diseases
Cervical Cancer

Cervical Cancer

Disease

Disease Profile

Cervical cancer is a malignancy arising in the cervix, often linked to persistent high-risk HPV infection. It remains an important global women's health cancer with preventable burden through vaccination and screening.

Category: Gynecologic malignancy
Prevalence: Estimated 297,908 women living with cervical cancer in the U.S. (2022)

ICD Codes

C53.9

Related News

Multiple Studies Link Accelerated Biological Aging to Rising Early-Onset Cancer in Younger Generations

Jun 29, 2026

Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.

CStone Receives FDA Clearance to Advance CS2009 Trispecific Antibody to Phase II Trials

Jun 12, 2026

The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.

HPV-Related Head and Neck Cancers Now Most Common HPV Malignancy in U.S.

Jun 10, 2026

Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.

NHS-Galleri Trial Misses Primary Endpoint but Shows 26% Reduction in Stage IV Cancer by Third Round

May 31, 2026

The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.

Immunotherapy, Targeted Therapy, and mRNA Vaccines Reshaping Cancer Care

May 07, 2026

Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.

FDA clears at-home HPV self-collection kit as study finds most women still prefer clinic screening

Apr 13, 2026

The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.

Tisotumab Vedotin Shows Similar Responses in Radiated and Non-Radiated Cervical Cancer Lesions

Apr 12, 2026

A retrospective review found tisotumab vedotin produced similar response rates in radiated and non-radiated cervical cancer lesions. In the 29-patient cohort, median overall survival was 11.0 months and median progression-free survival was 2.8 months.

HPV Vaccination Shows Sustained Protection Against Cervical Cancer

Apr 02, 2026

New research shows HPV vaccination provides sustained protection against invasive cervical cancer for over a decade, with vaccinated individuals showing significantly lower cancer rates. The study found 79% lower risk for those vaccinated before age 17, with protection lasting 13-15 years. Cervical cancer remains a major global health challenge, particularly in regions like India and the Caribbean where infection rates are high.

Australia's Medical Research Funding at Critical Juncture After 90 Years of NHMRC Success

Mar 29, 2026

Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.

FDA Approves Agilent's PD-L1 Companion Diagnostic for Esophageal Cancer

Mar 26, 2026

The FDA has approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying esophageal cancer patients eligible for Merck's KEYTRUDA immunotherapy. This marks the eighth FDA-approved indication for this diagnostic test with KEYTRUDA. The test helps identify patients whose tumors express PD-L1 for potential treatment with the anti-PD-1 therapy.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07612865	People's Hospital of Xinjiang Uygur Autonomous Region	COMPLETED	NA
NCT07605507	Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer	ACTIVE_NOT_RECRUITING	NA
NCT07597083	Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors	RECRUITING	NA
NCT07593066	PRIORITY Study in Cervical Cancer	NOT_YET_RECRUITING
NCT07586826	Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors	RECRUITING	PHASE2
NCT07584161	MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer	NOT_YET_RECRUITING	NA
NCT07581873	Education and Health in Women With Cervical Cancer	ACTIVE_NOT_RECRUITING	NA
NCT07576842	Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV	NOT_YET_RECRUITING	NA
NCT07557225	18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors	RECRUITING	NA
NCT07547267	The Effect of Vaginal Dilator Use	COMPLETED	NA